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March 31, 2009:1162–5hysicians do factor in this generalizability gap by favoring sound
linical judgment over the implementation of broad guidelines.
Roderick Tung, MD
UCLA Medical Center
rrhythmia Center
0833 Le Conte Avenue
H 307 CHS
os Angeles, California 90095
-mail: rtung@mednet.ucla.edu
doi:10.1016/j.jacc.2008.12.029
EFERENCES
. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implant-
able cardioverter-defibrillator therapy for the prevention of sudden
cardiac death. J Am Coll Cardiol 2008;52:1111–21.
. Epstein AE. Benefits of the implantable-cardioverter defibrillator. J Am
Coll Cardiol 2008;52:1122–7.
. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial
infarction. N Engl J Med 2008;359:2245–53.
. Bruch C, Bruch C, Sindermann J, Breithardt G, Gradaus R. Prevalence
and prognostic impact of comorbidities in heart failure patients with
implantable cardioverter defibrillator. Europace 2007;9:681–6.
. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac
conditions on survival after defibrillator implantation. J Am Coll
Cardiol 2007;49:2408–15.
. Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication
rates of cardiac rhythm management devices in ESRD patients. Am J
Kidney Dis 2007;49:656–63.
. Hreybe H, Razak E, Saba S. Effect of end-stage renal failure and
hemodialysis on mortality rates in implantable cardioverter-defibrillator
recipients. Pacing Clin Electrophysiol 2007;30:1091–5.
. Cuculich PS, Sanchez JM, Kerzner R, et al. Poor prognosis for patients
with chronic kidney disease despite ICD therapy for the primary prevention
of sudden death. Pacing Clin Electrophysiol 2007;30:207–13.
. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences
in the use of implantable cardioverter-defibrillators among patients
hospitalized with heart failure. JAMA 2007;298:1525–32.
eply
mproving patient outcomes requires therapy proven to enhance
uality of life and survival in a cost-effective fashion. Mindful of
his universally accepted notion in contemporary health care, I
elcome the opportunity to respond to Dr. Stamato’s comments on
he articles by Tung et al. (1) and Epstein (2) regarding evidence
upporting implantable cardioverter-defibrillator (ICD) therapy.
First, Dr. Stamato observes that because beta-blocker use is
imilarly underused in clinical trials and clinical practice, he
oncludes that although ICD therapy prolongs life, underutiliza-
ion “does cast some doubt on this conclusion.” The issue is not
hether ICDs prolong life. Multiple prospective randomized trials
ave unequivocally shown that ICDs prolong life in selected
atient populations (3). The real issue is that guidelines are not
ollowed, including both pharmacologic and nonpharmacologic
herapies. To improve outcomes, including quality of life and
urvival, practice must be evidence based; physicians must “get
ith the guidelines.” The best available data regarding quality of
ife and cost effectiveness support ICD use (4,5).
Second, the use of ICDs in “fewer than the predicted number of
atients” is noted by Dr. Stamato. Initial enthusiasm for most new
herapies tends to be tempered by the outcomes in clinical
edicine compared with clinical trails. Optimistic projections onhe implantation rate of ICDs were based on the prevalence ratherhan incidence of primary prevention ICD candidates. Media
ocus on device and lead reliability was not balanced with context
r perspective on the risks and benefits of ICD therapy. In true
ontext, many more patients have been hurt by unnecessary device
emoval and underutilization than injured by device failure (6).
Finally, all physicians agree that we need to more accurately
dentify not only patients who will benefit from device therapy but also
hose who will not, as discussed in my commentary. The excellent
rticles by Buxton et al. (7) and Goldenberg et al. (8) using retrospec-
ive data from the MUSTT (Multicenter UnSustained Tachycardia
rial) and MADIT II (Multicenter Automatic Defibrillator Implan-
ation Trial II) trials have moved us in this direction. Currently there
re ongoing trials addressing this concern (M2Risk [Risk Stratifica-
ion in MADIT II Type Patients], CARISMA [Cardiac Arrhyth-
ias and Risk Stratification After Myocardial Infarction], and the
EST/PREDICTS [Evaluating the Effectiveness of the LifeVest
efibrillator and Improving Methods for Determining the Use of
mplantable Cardioverter Defibrillators] study) (9–11).
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